glp 1 agonistleri Are Serious Anesthesia Risks of Semaglutide and Other GLP-1 Agonists Under-Recognized? Case Reports of Retained Solid Gastric Contents in Patients Undergoing Anesthesia The Impact of Glucagon-like Peptide-1

The results showed that the GLP-1RA group experienced a significant total body weight loss of 7.87% in one year, compared to 4.24% in the non-GLP-1RA group

People who experience semaglutide bloating may also reduce their fluid intake simply because they feel uncomfortably full

Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging

While GLP-1 medications were designed to regulate blood sugar, they also appear to have anti-inflammatory and pain-modulating effects

Obesity is a known risk factor for HS

Beyond pancreatic effects, GLP-1 slows gastric emptying, which moderates postprandial glucose excursions, and acts on central nervous system receptors to promote satiety and reduce appetite